# Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic Myeloma

> **NCT02784483** · PHASE1 · TERMINATED · sponsor: **Yale University** · enrollment: 2 (actual)

## Conditions studied

- Asymptomatic Myeloma

## Interventions

- **DRUG:** Atezolizumab (1200mg via IV infusion)

## Key facts

- **NCT ID:** NCT02784483
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-02-10
- **Primary completion:** 2017-09-15
- **Final completion:** 2019-04-22
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Based on FDA requirements
- **Last updated:** 2020-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02784483

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02784483, "Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic Myeloma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02784483. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*